"During the last years, rehabilitation activities have become more and more important, since the number of people with disabilities is growing for many reasons (e.g. ageing of the population and increase of chronic diseases). The introduction of leading-edge technologies in the treatment of disabilities is central in order to improve the efficiency of rehabilitation and the access to health-care services. The conjunction between Medicine and Engineering in the field of rehabilitation is the future for new effective methodologies. The objective of the project TechReh (Technology in Rehabilitation) was to build the capacities of Universities and Medical Centres in Uzbekistan in innovative rehabilitation techniques. TechReh focused on 3 main outputs: 1. Developing a Master Programme ""Computer Systems for Medicine"", 2. Modernising a Master Programme in Medical Rehabilitation and 3. Developing short courses for professionals from medical and technical fields.The activities included the establishment of an office with state of the art equipment in each Partner University in Uzbekistan, which should play a crucial role in promoting research and the use of technology in medical rehabilitation."

Psoriatic Arthritis (PsA) is a chronic, progressive, inflammatory disease affecting 1-2% of the general population, while manifesting in up to 30% of people with psoriasis (PsO). The transition from health to PsA is currently untraceable; diagnosis of early PsA is challenging even in PsO patients. Untimely diagnosis is common and contributes to early deterioration of quality of life, also increasing the burden of the multiple comorbidities associated with PsA. In this vein, iPROLEPSIS aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale/multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioural) data, digital phenotyping of inflammatory symptoms with emphasis on tracking of motor manifestations using smart devices and wearables, novel optoacoustic imaging-based markers of PsA in the skin and joints, and investigation of the role of mast cells in the PsA transition, to identify key drivers of the disease and support personalized models for PsA risk/progression prediction and monitoring as well as associated inflammation detection and severity assessment. To ultimately advance PsA diagnosis and care, the models will be translated into a digital health ecosystem comprising dependable tools for supporting healthcare professionals in disease screening, monitoring and treatment via quantitative, explainable evidence, and empowering people with/at risk of PsA with tailored insights and preventive interventions based on actionable factors for educated health management. The project will steer its research and development efforts following a trustworthy framework for ethical, lawful, and robust AI, and a user-centered co-creation approach based on constant involvement of key stakeholders during the design, development, and testing of the digital health ecosystem, securing successful integration of the latter in the continuum of care.

RAPID-MIX brings together 3 leading research institutions with 4 dynamic creative industries SMEs and 1 leading wearable technology SME in a technology transfer consortium to bring to market innovative interface products for music, gaming, and e-Health applications. RAPID-MIX uses an intensely user-centric development process to gauge industry pull and end-user desire for new modes of interaction that integrate physiological human sensing, gesture and body language, and smart information analysis and adaptation. Physiological biosignals (EEG, EMG) are used in multimodal hardware configurations with motion sensors and haptic actuators. Advanced machine learning software adapts to expressive human variation, allowing fluid interaction and personalized experience. An iterative, rapid development cycle of hardware prototyping, software development, and application integration accelerates the availability of advanced interface technologies to industry partners. An equally user-centric evaluation phase assures market validation and end-user relevance and usability, feeding back to subsequent design cycles and informing ultimate market deployment. The RAPID-MIX consortium leverages contemporary dissemination channels such as crowd funding, industry trade shows, and contributions to the DIY community to raise awareness across the professional and consumer landscapes of novel interface technologies. Project output is encapsulated in an Open Source RAPID-API exposing application level access to software libraries, hardware designs, and middleware layers. This will enable creative partner SMEs to build a new range of products called Multimodal Interactive eXpressive systems (MIX). It also allows broader industries such as quantified self, and DIY communities, to use the API in their own products in cost effective ways. This assures the legacy of RAPID-MIX and marks its contribution to European competitiveness in rapidly evolving markets for embodied interaction technologies.

Nowadays, chronic diseases and co-morbidities have to be managed during a long period of time among health and social care systems, thus a big amount of budget and resources should be destined to them. If these patients could stay at home during their illnesses exacerbations, a big amount of resources could be saved, a more independent like and a higher quality of life for these patients could be reached due to fewer hospitalizations, more remote control of their health status by care services and by self- knowledge of their own disease. For this purpose POLYCARE will provide ICT solutions that will foster real integrated care between health and social care following a new methodology that will be defined with European focus. These ICT solutions will be based on a collaborative environment between health and social care services that will help to share information between them and a Decision Support System will provide alerts, recommendations and adverse effects due to medicaments interaction in the case of poly-medicated patients. On the other hand, we will take care of patients by providing devices and personalized apps for being involved at their self-health management and fostering interaction with medical and social care services.The project will be focused on home hospitalization (patient treatment at as in the hospital). The target patients are chronic patient in acute phases, who are usually elderly people. Thus, patients’ apps will be based on gamification basis in order to be more attractive and accessible; to measure vital signals to control their health status will be provided by optimized wearables devices so that they not need any specific knowledge. Besides, informal care givers and social professionals will support patients on these new tools and will include additional data to monitor. These innovation features will be carried out by a strong consortium headed by a company leading ICT solutions for health fostering business opportunities to all.